Semaglutide became the first obesity drug to reduce major cardiovascular events by 20% (SELECT trial), while next-generation peptide drugs like tirzepatide and retatrutide are achieving up to 24% weight loss with potentially greater heart benefits.
20% MACE ReductionSemaglutide became the first obesity drug to significantly reduce major cardiovascular events in the SELECT trial, breaking the historical 'weight loss paradox'
What the researchers found
The review highlights the paradigm shift in obesity pharmacotherapy driven by peptide-based drugs:
- Semaglutide: first obesity drug to demonstrate a significant 20% reduction in major adverse cardiovascular events (MACE) in the SELECT trial, though secondary endpoints were neutral
- Tirzepatide and retatrutide: next-generation multi-receptor agonists achieving up to 24% weight loss
- These drugs exert pleiotropic effects beyond weight loss: anti-inflammatory properties, improved endothelial function, and anti-atherosclerotic effects that may contribute to cardiovascular protection
- Lifestyle modifications, while foundational, have limited long-term efficacy as most individuals regain lost weight
- Bariatric surgery remains most effective for long-term weight management but has limited accessibility
Why it matters
Obesity affects over 1 billion people worldwide and is the leading modifiable risk factor for cardiovascular disease. The fact that semaglutide — a peptide drug — is the first obesity medication to prove cardiovascular risk reduction is a watershed moment in medicine. It validates the entire approach of using incretin-based peptide therapeutics not just for weight loss but for cardiovascular protection, potentially saving millions of lives.
How the study worked
Narrative review synthesizing clinical trial data, cardiovascular outcome studies (including SELECT), and emerging research on next-generation obesity pharmacotherapies. The review covers the evolution from lifestyle interventions and bariatric surgery to GLP-1 receptor agonists and multi-receptor agonists.
What this study cannot tell us
As a narrative review, this synthesizes existing literature without new data. The SELECT trial's neutral secondary endpoints warrant caution about the breadth of cardiovascular benefit. The newest agents (retatrutide) have weight loss data but lack completed cardiovascular outcome trials. Long-term safety data (beyond 2-3 years) is limited for most agents. Cost and access remain significant barriers to widespread adoption of these expensive peptide drugs.
How to read the evidence
This is a narrative review that synthesizes high-quality evidence including large randomized cardiovascular outcome trials (SELECT). While the review itself is not systematic, the underlying evidence it discusses — particularly the SELECT trial — represents some of the strongest clinical evidence in obesity medicine.
When this study was published
Published in 2025, this review covers the most current landscape of obesity pharmacotherapy including the landmark SELECT trial results and emerging data on next-generation multi-receptor agonists.
The bigger picture
This review captures the most transformative period in obesity medicine history. GLP-1 receptor agonists and multi-receptor peptide agonists are not just weight loss drugs — they're redefining how we think about the relationship between metabolism, inflammation, and cardiovascular disease. The progression from single-receptor (GLP-1) to dual-receptor (GIP/GLP-1: tirzepatide) to triple-receptor (GLP-1/GIP/glucagon: retatrutide) agonists shows the field rapidly advancing toward ever more effective peptide-based therapeutics.
Questions still open
- Will the more potent weight loss achieved by tirzepatide and retatrutide translate into even greater cardiovascular event reduction than semaglutide?
- Are the cardiovascular benefits of GLP-1 drugs driven primarily by weight loss, or by their independent anti-inflammatory and vascular effects?
- How should clinicians decide between peptide pharmacotherapy and bariatric surgery for individual patients?
Common questions
What is the 'weight loss paradox' and how did GLP-1 drugs break it?
What are the next-generation peptide obesity drugs beyond semaglutide?
Read the original research
Breaking the weight loss paradox: from weight reduction to cardiovascular benefit in obesity treatment.
Polish archives of internal medicine, 135(3)
Citation
Gajos, Grzegorz. (2025). Breaking the weight loss paradox: from weight reduction to cardiovascular benefit in obesity treatment.. Polish archives of internal medicine, 135(3). https://doi.org/10.20452/pamw.16983